PDCD1 and non-small cell lung carcinoma: However, higher histidine levels in early on-treatment serum from advanced NSCLC patients receiving anti-PD1 therapy are associated with favorable OS and PFS; thus, histidine has been proposed as a potential predictive biomarker of the response to PD-1 blockade therapy in advanced NSCLC patients [45].